Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
暂无分享,去创建一个
[1] Hannah C. Beird,et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma , 2017, npj Genomic Medicine.
[2] D. Gabrilovich,et al. Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.
[3] J. Roszik,et al. Targeting iNOS to increase efficacy of immunotherapies , 2017, Human vaccines & immunotherapeutics.
[4] D. Curiel,et al. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells , 2017, Proceedings of the National Academy of Sciences.
[5] M. Mann,et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.
[6] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[7] M. Davies,et al. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma , 2016, Clinical Cancer Research.
[8] P. Thevenot,et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. , 2015, Cancer research.
[9] N. Tan,et al. Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation , 2014, Oncotarget.
[10] A. Popolo,et al. l-Arginine and its metabolites in kidney and cardiovascular disease , 2014, Amino Acids.
[11] S. Ambs,et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.
[12] W. Fast,et al. Developing an Irreversible Inhibitor of Human DDAH‐1, an Enzyme Upregulated in Melanoma , 2014, ChemMedChem.
[13] A. Sikora,et al. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] C. Lindermayr,et al. Erratum: Nitric oxide-based protein modification: formation and site-specificity of protein S-nitrosylation , 2013, Front. Plant Sci..
[15] C. Lindermayr,et al. Nitric oxide-based protein modification: formation and site-specificity of protein S-nitrosylation , 2013, Front. Plant Sci..
[16] Jung-ki Yoon,et al. Arginine deprivation therapy for malignant melanoma , 2012, Clinical pharmacology : advances and applications.
[17] A. Rossary,et al. Altered functions of natural killer cells in response to L-Arginine availability. , 2012, Cellular immunology.
[18] K. Tanese,et al. The role of melanoma tumor‐derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10 , 2012, International journal of cancer.
[19] U. Förstermann,et al. Nitric oxide synthases: regulation and function. , 2012, European heart journal.
[20] Asif Ali,et al. Biochemistry of Nitric Oxide , 2011, Indian Journal of Clinical Biochemistry.
[21] R. Mikkelsen,et al. Protein tyrosine nitration in cellular signal transduction pathways , 2010, Journal of receptor and signal transduction research.
[22] R. Medzhitov. Inflammation 2010: New Adventures of an Old Flame , 2010, Cell.
[23] P. Allen,et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. , 2009, Cancer research.
[24] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[25] D. Mougiakakos,et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma , 2009, Cancer Immunology, Immunotherapy.
[26] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[27] M. Wangpaichitr,et al. Arginine deprivation as a targeted therapy for cancer. , 2008, Current pharmaceutical design.
[28] D. Quiceno,et al. L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.
[29] L. Broemeling,et al. Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.
[30] D. S. Lind,et al. Arginine and cancer. , 2004, The Journal of nutrition.
[31] A. Barilli,et al. The stimulation of arginine transport by TNFα in human endothelial cells depends on NF-κB activation , 2004 .
[32] M. Hatzoglou,et al. Regulation of cationic amino acid transport: the story of the CAT-1 transporter. , 2004, Annual review of nutrition.
[33] E. Grimm,et al. Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines* , 2004, Journal of Biological Chemistry.
[34] A. Barilli,et al. The stimulation of arginine transport by TNFalpha in human endothelial cells depends on NF-kappaB activation. , 2004, Biochimica et biophysica acta.
[35] J. Cunningham,et al. Cytokines and Insulin Induce Cationic Amino Acid Transporter (CAT) Expression in Cardiac Myocytes , 1996, The Journal of Biological Chemistry.